Rapamycin and cyclosporine A treatment: a novel regimen to prevent chronic allograft rejection in sensitized hosts.
Wasowska
B
B
Harvard Medical School, Division of Immunology, Beth Israel Hospital, Boston, MA 02115, USA.
Hancock
W W
WW
Onodera
K
K
Korom
S
S
Stadlbauer
T H
TH
Zheng
X X
XX
Strom
T B
TB
Kupiec-Weglinski
J W
JW
D001161:Arteriosclerosis / Q000473:pathology / Q000503:physiopathology; D018932:Chemokine CCL2 / Q000096:biosynthesis; D018946:Chemokine CCL5 / Q000096:biosynthesis; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use*; D016207:Cytokines / Q000096:biosynthesis; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007114:Immunization; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011090:Polyenes / Q000627:therapeutic use*; D011183:Postoperative Complications; D020123:Sirolimus; D014158:Transcription, Genetic; D014184:Transplantation, Homologous
D018932:Chemokine CCL2; D018946:Chemokine CCL5; D016207:Cytokines; D007166:Immunosuppressive Agents; D011090:Polyenes; D016572:Cyclosporine; D020123:Sirolimus